TetraGenetics announces discovery of functional antibodies against Nav1.8

BY      |     December 15, 2020

TetraGenetics, a biopharmaceutical company developing novel antibody therapeutics for ion-channel related diseases, announced the discovery of functional antibodies against Nav1.8.

The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins.

A multi-platform antibody discovery approach (phage display, llama immunization) has enabled TetraGenetics to identify functional anti-Nav1.8 antibodies that selectively inhibit Nav1.8 currents in a recombinant cell line. A lead antibody molecule demonstrates significant inhibition of activity in sensitive human dorsal root ganglion (DRG) neurons, at a level that translates to clinical analgesia.

“The discovery of these functional antibodies represents a clear industry breakthrough and accelerates the company’s transition from research to full scale drug development,” said Doug Kahn, CEO of TetraGenetics.

A video introduction to TetraGenetics presentation at the Antibody Engineering & Therapeutics Virtual Conference is available here.

Read the press release here.

Read more about TetraGenetics here.

Image by Artem Kondratskyi

Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at
Alternatively, you can leave your comments on LinkedIn or Twitter.